Was ist bei SYBB - Synsorb heute los?? - 500 Beiträge pro Seite

[Kursfuzzi]

Hallo,
weis einer von Euch warum Synsorb (SYBB) heute so stark Abgeht??????????
Riesen Volumen und hoher Zugewinn / nach Riesenabsturz!!!!

Hab keine News gefunden, NUR ZOCK?????
Gruß
Fuzzi

[benefactor [KommA]]

Da scheint aber heute einer ganz scharf auf die Aktien von Synsorb zu sein! Da wird wohl was in naher Zukunft passieren.

[benefactor [KommA]]

Da hat jetzt schon einer 5,4% vom ganzen Unternehmen in nur 3 Stunden gekauft.

[Bombenleger]

Thursday March 28, 6:43 pm Eastern Time

Press Release

SOURCE: SYNSORB Biotech Inc.

SYNSORB Biotech Inc. and Oncolytics Biotech Inc. Announce Regulatory
Approval to Distribute Oncolytics` Shares held by SYNSORB to SYNSORB
Shareholders

CALGARY, March 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (NASDAQ: ONCY - news; TSE: ONC - news;
``Oncolytics``) and SYNSORB Biotech Inc. (NASDAQ: SYBB - news), (TSE: SYB - news; ``SYNSORB``) announced today
that they have received approval from the Alberta Securities Commission to have the previously issued 4,725,000 common shares
in the capital of Oncolytics held in escrow by SYNSORB released from such escrow without any trading restrictions provided that
at least 4,000,000 of the shares are distributed to the SYNSORB shareholders. The remaining shares will be released to
SYNSORB for its account without any trading restrictions.

The early release from escrow is subject to approval by the Oncolytics shareholders (by at least a majority of votes cast on the
resolution, with the shares held by SYNSORB not being voted) at a meeting to be held on or about May 7, 2002 and approval by
the SYNSORB shareholders (by at least two-thirds of the votes cast on the resolution) at a meeting to be held on or about May 7,
2002. Provided the shareholders of each of Oncolytics and SYNSORB approve the early release from escrow, it is anticipated
that SYNSORB will distribute the Oncolytics shares to its shareholders promptly after the meetings.

Bill Hogg, President and Chief Executive Officer of SYNSORB stated ``The distribution of eighty-five percent of our Oncolytics
holdings to our shareholders is a critical step in restructuring our business. With our current number of shares outstanding, at the
time of distribution our shareholders would receive approximately 0.101 of an Oncolytics share for each SYNSORB share they
own. Furthermore, after this distribution, the SYNSORB asset base and tax pools would still represent a good opportunity for
value generation.``

Dr. Brad Thompson, President and Chief Executive Officer of Oncolytics, stated ``The release of these shares held by SYNSORB
and distribution to the SYNSORB shareholders will significantly broaden our shareholder base and increase the public float of
Oncolytics shares by approximately one-third. We view this as a positive development in the long-term outlook for Oncolytics and
its current shareholders.``

Provided the transaction is approved by the shareholders of Oncolytics and SYNSORB, Oncolytics will receive 1,500,000
common shares (and the right to receive 400,000 additional shares upon the attainment of certain milestones) currently held by
SYNSORB in the capital of BCY LifeSciences Inc., a CDNX listed (CDNX:BCY - news) pharmaceutical company with license
rights to technologies to treat certain diseases of the respiratory tract. In addition, if the distribution is approved, the directors of
SYNSORB on the Board of Directors of Oncolytics will not stand for election as directors of Oncolytics at the upcoming Annual
and Special Meeting of Oncolytics to be held on May 16, 2002.

[benefactor [KommA]]

Hat sich ganz nett entwickelt!

[merx]

Synsorb Update Shareholders on Recent Developments
Friday November 1, 4:39 pm ET


CALGARY, Nov. 1 /PRNewswire-FirstCall/ - Synsorb Biotech Inc. (TSE: SYB - News). Gerry C. Quinn, the chairman of the Board of Directors is pleased to update SYNSORB shareholders with respect to recent developments at the Company.
ADVERTISEMENT


The Board continues to seek actions that will maximize the return for Synsorb shareholders from its present asset base while seeking a new business focus and management team for Synsorb.

Throughout 2002, the Board has sought to find a pharmaceutical company or other industry buyer to buy SYNSORB`s drug manufacturing facility with no success. Accordingly, the Board is implementing a strategy to dispose of its various assets individually.

SYNSORB`s 31,000 square foot manufacturing plant in Calgary has been listed for sale with J.J. Barnicke Ltd., a commercial real estate broker, with an asking price of $3,525,000.

SYNSORB has retained ICOWorks Services Ltd., an experienced Alberta based auction house, to auction the manufacturing, lab and related equipment, formerly part of Synsorb`s manufacturing facility. The public auction of this equipment will be scheduled for mid-January, 2003.

Synsorb continues to seek a buyer for its patents and related technology. If no buyer is found, the technology portfolio may be abandoned due to the high cost of maintaining these rights.

Synsorb Board has appointed a special committee of the board comprised of Tim Tycholis (Chair), Jim Silye and Gerry Quinn to seek a significant transaction for Synsorb, which may include an acquisition of a new business or assets, appointment of a new management team or similar transaction. In this connection, the Synsorb board has retained Network Capital Inc., of Calgary, Alberta as its financial advisor seeking such a transaction that will maximize value for SYNSORB shareholders. Network Capital Inc. is a Calgary based financial advisory firm dedicated to providing venture capital, strategic direction and financial advise to Canadian companies. The principals of Network have substantial experience in capital raising and corporate reorganizations.

Mr. Gerry Quinn has replaced Mr. David Tonken as chairman of the Synsorb Board. Mr. Tonken remains a member of the Board.

Synsorb Biotech Inc. is a publicly traded company listed on the Toronto Stock Exchange.




--------------------------------------------------------------------------------
Source: SYNSORB Biotech Inc.

[Willem_de_dridde]

Das kann man wohl sagen:

[einheld]

Synsorb Makeover...To Become a New Oil And Gas Entity.

CALGARY, Jan 06, 2003 (Canada NewsWire via COMTEX) -- Synsorb Biotech Inc. ("Synsorb") (SYB - Toronto Stock Exchange) announces today that it has entered into an agreement with a small investor group led by David Tuer, that will see the former pharmaceutical research company transformed into an oil and gas enterprise. If approved by shareholders, Synsorb will issue approximately $3.5 million of secured debentures together with 5.5 million common share purchase warrants with 5.5 million associated voting preferred shares attached thereto. If all conversion rights are exercised, the Tuer-led group will own approximately 45% of the common shares of Synsorb. Mr. Tuer has been appointed as the Chairman and Chief Executive Officer of Synsorb.

Mr. Tuer is a petroleum engineer who last served as the President and Chief Executive Officer of PanCanadian Petroleum Ltd. Under Mr. Tuer`s leadership PanCanadian grew from a market capitalization of $5.5 billion to $10 billion in six years and emerged from control by Canadian Pacific Limited to become a fully independent entity traded on the Toronto and New York stock exchanges.

Mr. Tuer commented that: "I am very excited about the opportunity to build a full cycle oil and gas company from the ground floor. The attributes of Synsorb and the timing in the Canadian oil and gas industry will allow me to bring together a strong management team and aggressively pursue new investment opportunities. It is expected that the company will undergo a name change to be proposed within a management information circular to be mailed out following due diligence. The company`s business strategy will have a dual focus on exploration and development, combined with an aggressive acquisition strategy with a particular focus on natural gas opportunities."

Gerry Quinn, the outgoing chairman of Synsorb, said: "This is an excellent opportunity for the Synsorb shareholders. We are extremely fortunate to have an individual with David Tuer`s business experience and track record lead Synsorb along a promising new path."

The transaction is subject to shareholder approval, with all of the directors and a significant shareholder having agreed to vote in favor of the transaction. All option holders, holding in the aggregate options to acquire 275,000 common shares at $0.70 per share, have agreed to exercise their options prior to completion of the transaction. Synsorb has agreed to pay a non-completion fee if the transaction is not completed under certain conditions. Synsorb has agreed to terminate discussion with other parties and will not solicit any other proposals. The Board of Directors will recommend that shareholders vote in favour of the proposed transaction.

Completion of the transaction is subject to receipt of all necessary regulatory approvals, including the approval of the Toronto Stock Exchange, and execution of definitive documentation following completion of the investor group`s due diligence reviews by no later than January 31, 2003. This transaction cannot close until the required shareholder approval is obtained. Synsorb has advised the investor group that it expects to be in a position to settle the current class action suits against it at little or no cost to Synsorb.

There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Synsorb should be considered highly speculative. Neither the Toronto Stock Exchange nor the TSX Venture Exchange has approved or disapproved the information contained herein.

Forward-Looking Statements. The above disclosure contains certain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond Synsorb`s control, including: the impact of general economic conditions in the U.S. and Canada, fluctuations in product prices and in foreign exchange or interest rates, industry conditions, the adoption of new environmental laws and regulations and changes in how they are interpreted and enforced, increased competition, the lack of availability of qualified personnel or management, stock market volatility and market valuations of companies with respect to the announced transactions, and the final valuations thereof, and obtaining required approvals of regulatory authorities. Synsorb`s actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that Synsorb will derive therefrom.

%SEDAR: 00002576E

VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=50525

For further information: Jim Silye, Synsorb Biotech Inc., [phone]
or Jane Johnson, Executive Assistant to David Tuer, at [phone]

News release via Canada NewsWire, Calgary 403-269-7605

Hoffen wir damit auf einen Neuanfang!